Belgian Personal Products Stock News

Montea Comm. VA overview Montea Comm. VA (ENXTBR:MONT) is back in focus after investors reacted to its recent share performance, with the stock showing mixed returns over the past week, month and past 3 months. The logistics focused real estate group, active across Belgium, the Netherlands, France and Germany, now trades around €74. This has prompted fresh interest in how its long term total returns compare with its current valuation profile. See our latest analysis for Montea Comm...

Aedifica/SA (ENXTBR:AED) has wrapped up FY 2025 with fourth quarter revenue of €90.5 million and basic EPS of €1.06. Trailing 12 month figures show revenue of €369.6 million and EPS of €5.14. The company has reported revenue increasing from €346.5 million to €369.6 million on a trailing 12 month basis, with EPS rising from €4.31 to €5.14 over the same period. Quarterly revenue ranged between €90.2 million and €95.4 million, and EPS between €0.71 and €1.70 across the last six reported...

It's been a good week for Anheuser-Busch InBev SA/NV ( EBR:ABI ) shareholders, because the company has just released...

Shareholders might have noticed that KBC Group NV ( EBR:KBC ) filed its yearly result this time last week. The early...

When you buy shares in a company, it's worth keeping in mind the possibility that it could fail, and you could lose...

Competitive pressure in generalized myasthenia gravis The European Commission’s approval of Amgen’s Uplizna for generalized myasthenia gravis puts fresh competitive pressure on UCB (ENXTBR:UCB) in a treatment area where it already markets RYSTIGGO and ZILBRYSQ. See our latest analysis for UCB. Against this backdrop of fresh competition in generalized myasthenia gravis, UCB’s share price has climbed to €279.5, with a 90 day share price return of 22.27% and a 1 year total shareholder return of...

Recent share performance and current snapshot SCR-Sibelco (ENXTBR:094426466) has been relatively stable in the very short term, with the share price flat over the past day and a modest 1.3% gain over the past week. Over longer periods, the picture is more mixed, with a small decline over the past month, a 3% gain over the past 3 months, and negative returns year to date and over the past year and the past 3 to 5 years. See our latest analysis for SCR-Sibelco. That mix of a 3.03% 90 day share...

Orange Belgium S.A.'s ( EBR:OBEL ) solid earnings announcement recently didn't do much to the stock price. Our analysis...

Most readers would already be aware that Cenergy Holdings' (EBR:CENER) stock increased significantly by 30% over the...

Sipef (ENXTBR:SIP) has reported fresh FY 2025 numbers, with first half revenue of US$250.4 million and EPS of US$5.54, set against trailing 12 month revenue of US$570.4 million and EPS of US$12.05 that came with 90.5% earnings growth over the past year. The company has seen revenue move from US$203.1 million and EPS of US$2.41 in 1H 2024 to US$239.3 million and EPS of US$3.91 in 2H 2024, before reaching the latest 1H 2025 levels. This progression gives investors a clearer run rate on both the...

If you are wondering whether Umicore is still attractively priced after a volatile few years, this article will walk through what the current share price might imply about value. Over the last year, the share price is up 102.8%, even though the 7 day and 30 day returns are 3.2% and 1.8% declines and the 3 year and 5 year returns are 36.6% and 56.1% declines, with the stock most recently closing at €19.05. These moves sit against a backdrop of ongoing attention on Umicore's role in materials...

Ontex Group (ENXTBR:ONTEX) has just posted its FY 2025 first half results, with revenue of €880.3 million and a basic EPS loss of €0.05, setting a cautious tone for how you might think about the latest numbers. Over the previous two halves in 2024, the company saw revenue move from €916.1 million in the first half to €944.4 million in the second half, while basic EPS shifted from €0.12 to €0.14, giving you a clear view of how the current setback compares to more recent profitability. With...

Montea Comm. VA (ENXTBR:MONT) has put fresh numbers on the table for FY 2025, with Q4 revenue of €56.5 million and basic EPS of €2.09, alongside trailing twelve month revenue of €167.1 million and EPS of €7.09. The company has seen quarterly revenue move from €47.5 million in Q4 2024 to €56.5 million in Q4 2025, while basic EPS shifted from €2.17 to €2.09 over the same period. This sets up a results season in which investors are weighing income appeal and reported earnings power against how...

Nextensa (ENXTBR:NEXTA) has put fresh numbers on the table for FY 2025, with first half revenue of €50.7m and basic EPS of €1.96, setting a clear marker for how the year is tracking so far. The company has seen revenue move from €65.1m in the first half of 2024 to €59.9m in the second half and then to €50.7m in the first half of 2025, while EPS shifted from €1.39 to an EPS loss of €2.48 and then back to EPS of €1.96. This gives investors a clear view of how the income line has been...

Anheuser-Busch InBev (ENXTBR:ABI) has wrapped up FY 2025 with fourth quarter revenue of about US$15.6b and basic EPS of US$0.99, rounding out a year where trailing 12 month revenue reached roughly US$59.3b and EPS came in at US$3.45. Over the past few quarters, revenue has moved from US$14.8b in Q4 2024 to US$15.0b in Q2 2025 and US$15.1b in Q3 2025, while quarterly EPS has ranged between US$0.53 and US$1.08, setting up a picture of higher trailing profitability alongside a net profit margin...

Barco (ENXTBR:BAR) has wrapped up FY 2025 with second half revenue of €509.5 million and basic EPS of €0.58, while the trailing twelve months show revenue of €963.8 million and basic EPS of €0.85, setting a clear benchmark for how the business is currently performing. The company has seen revenue move from €946.6 million to €963.8 million on a trailing basis, with basic EPS shifting from €0.71 to €0.85, giving investors a cleaner read on how profit per share is tracking alongside top line...

Fagron (ENXTBR:FAGR) reports strong full-year 2025 results. The company announces 12 acquisitions across all regions and segments. Management highlights active M&A integration alongside ongoing operations. Fagron, a global player in pharmaceutical compounding, is drawing attention with its 2025 performance and extensive deal activity. For investors following healthcare suppliers, this combination of solid reported results and a busy acquisition calendar helps frame how the company is...

The most you can lose on any stock (assuming you don't use leverage) is 100% of your money. But on the bright side, you...

Why KBC Group (ENXTBR:KBC) is on investors’ radar today KBC Group (ENXTBR:KBC) has attracted attention after recent share price moves, with the stock showing mixed short term returns and multi year total returns that may prompt a closer look at its current valuation. See our latest analysis for KBC Group. Recent trading has cooled slightly, with a 1 day share price return of a 4.04% decline and a 7 day share price return of a 2.14% decline. However, a 1 year total shareholder return of 46.51%...

To the annoyance of some shareholders, Option NV ( EBR:OPTI ) shares are down a considerable 27% in the last month...

Banqup Group SA ( EBR:BANQ ) shareholders would be excited to see that the share price has had a great month, posting a...

If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Firstly, we'd...

BNP Paribas Asset Management has disclosed crossing the 3% legal threshold of direct voting rights in Umicore. The disclosure reflects an increased stake that now exceeds the mandatory reporting level for shareholder voting power. Umicore (ENXTBR:UMI) is trading at €18.8, with the share price up 81.3% over the past year, while longer term returns over 3 and 5 years show declines of 37.6% and 55.1% respectively. This mix of strong recent performance and weaker multi year returns gives a...

Econocom Group (ENXTBR:ECONB) closed FY 2025 with second half revenue of €1.5b and net income from continuing operations of €34.5m, while trailing twelve month net income from continuing operations reached €53.2m. The company has seen half year revenue move from €1.4b in H2 2024 to €1.5b in H2 2025, with trailing twelve month revenue rising from €2.7b to €2.9b over the same comparison window. With net profit margins running at 1.8% over the last year and earnings growth expectations in focus,...